March 22 (Reuters) – Roche (ROG.S) and Eli Lilly and Co (LLY.N) are joining forces to develop a blood test for Alzheimer’s disease, and plan to kick off a two-year clinical trial involving hundreds of volunteers with the aim of winning U.S. regulatory approval. The effort, unveiled in a statement on Wednesday, comes as Lilly as well as Eisai (4523.T) and Biogen (BIIB.O) are gearing up to sell drugs aimed at slowing the advance of the mind-robbing illness, but their use will require a diagnosis at earlier disease stages than is the norm today. Roche Holding AG would recruit several hundred volunteers with early signs of dementia over the next 18 to 24 months with trial data potentially ready for a U.S. regulatory filing in 2025, Bruce Jordan, leader of Personalized Healthcare Solutions at Roche Diagnostics, told Reuters. The U.S. Food and Drug Administration has asked Roche to recruit a significant number of patients at primary care facilities ...
Researchers at Washington University School of Medicine in St. Louis have developed a new blood test that can detect Alzheimer’s disease in its early stages. The test looks for a specific protein called tau, which is known to be a key biomarker of Alzheimer’s. Currently, the most common way to diagnose Alzheimer’s disease is through cognitive testing and brain imaging scans. However, these methods can be costly and invasive. Additionally, by the time symptoms appear, the disease has already caused significant damage to the brain. The new blood test offers a non-invasive and potentially more accessible way to diagnose Alzheimer’s disease early on, when treatments may be more effective. The study, published in the journal Nature Medicine, involved analyzing blood samples from 158 individuals, including healthy adults, individuals with mild cognitive impairment, and individuals with Alzheimer’s disease. The researchers used a technique called mass spectrometry to measure levels ...
Source:https://www.medicalnewstoday.com/articles/327291.php#1 Using mouse models of Alzheimer’s disease, researchers have been looking into a new approach to slow down the progression of this neurodegenerative disease — a ketone ester-rich diet.Could a new therapeutic approach help slow down Alzheimer’s disease? Researchers from the NIH investigate.To get the energy it needs to function correctly, the body usually relies on glucose (a simple sugar), which results from the digestion of carbohydrates. When there is not enough glucose to rely on, the body will burn fat instead. This is a process called ketosis, and it is the principle that ketogenic — or keto — diets rely on.Keto diets are typically low in carbohydrates and high in fats, and this imbalance in resources produces ketosis. But there is also another way of inducing ketosis that does not involve making this dietary shift. It involves taking supplements containing ketone ester, which have the same effect. Researchers have ...
In a breakthrough finding, revealed through the final analysis of a mid-stage trial, Japanese pharmaceutical firm, Eisai Co and Biogen Inc’s drug for Alzheimer’s proved beneficial for patients who received the highest dose.
EIP Pharma raised $20.5 million series B funding to support Neflamapimod, the phase 2b program of its Alzheimer treatment. The funding is also to build the team and to support other research studies related to central nervous system disorders.
Washington University School of Medicine sleep specialist Yo-El Ju, MD, led a research team that found circadian rhythm disruptions occur in people whose memories are intact but whose brain scans show early, preclinical evidence of Alzheimer's disease. She previously had discovered that people with clinical symptoms of Alzheimer's have disturbances in their internal body clocks that affect the sleep/wake cycle. Credit: Washington University School of Medicine.
Amgen and Basel, Switzerland-based Novartis announced they have expanded their collaboration with the Banner Alzheimer’s Institute (BAI) to launch a new clinical trial in Alzheimer’s.
Buildups of "clumpy" proteins in the brain are well-known hallmarks of Alzheimer's, but not everyone who has them goes on to develop this neurodegenerative disease. Why is that? New research investigates.
AbbVie (ABBV), a global biopharmaceutical company, and Alector, a privately owned biotechnology company, announced a global strategic collaboration to develop and commercialize medicines to treat Alzheimer's disease and other neurodegenerative disorders.
The future of researching ways to prevent AD should probably focus on people at risk for developing the disease, said researchers, and should highlight how to improve management of chronic health conditions and education about living healthier.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.